Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Young Ho Kim

Chief Executive Officer

AT-31 BIO Inc.

Daegu, South Korea

AT-31 BIO Inc. has developed GJK-012, a patent-pending immunosuppressant for use in innovative eye drops for Sjögren's syndrome dry eye disease. We seek investors, R&D co-developers, and Big Pharma M&A/licensing partners to advance clinical trials.

My organisation

AT-31 BIO Inc.

AT-31 BIO Inc.

SME

Daegu, South Korea

AT-31 BIO Inc. aims to discover new drug candidates and successfully develop innovate new drugs which contribute to a healthy and happy society by overcoming diseases caused by inappropriate operations of the immune system. Currently, we are conducting empirical studies using cutting-edge research techniques on the immunosuppressive efficacy of monosaccharide which can be mass-produceed from our own enzymatic complete hydrolysis of agarose. We are also conducting preclinical studies using animal disease models to explore and establish indications for our potential drug candidates. Through these research approaches, We hope to open new horizons in the prevention and treatment of autoimmune diseases, transplant rejection, and hypersensitivity immune diseases, which are representative of unmet medical needs.
Read more

About me

  • Founder & CEO of AT-31 BIO Inc., Republic of Korea

  • Professor Emeritus of School of Life Sciences, Kyungpook National University, Republic of Korea

  • Former President, The Korean Society of Life Science

  • Former Vice President, The Korean Society for Microbiology and Biotechnology

  • Former Technical Advisor, Astrogen Co., Ltd., Republic of Korea

  • Visiting Professor, Enzyme Research Institute, Tokushima University, Japan

  • Post-Doc. / Visiting Professor, Clinical Immunology Section, Gerontology Research Center/NIA, NIH, MD, USA

  • Ph.D. Kyungpook National University, Republic of Korea

Marketplace (2)

  • Partnership

    Areas of Interest for international collaboration

    Seeking to collaborate with pharmaceutical companies and researchers being committed to manufacture drugs for treatment of autoimmune diseases (Sjögren’s syndrome dry eye, IBD, AD, and MS) to develop new drugs containig GJK-012 as the active ingredient.

    Author

    Young Ho Kim

    Chief Executive Officer at AT-31 BIO Inc.

    Daegu, South Korea

  • Partnership

    Areas of Interest for international collaboration

    Seeking to collaborate with pharmaceutical companies and researchers being committed to manufacture drugs for treatment of autoimmune diseases (Sjögren’s syndrome dry eye, IBD, AD, and MS) to develop new drugs containig GJK-012 as the active ingredient.

    Author

    Young Ho Kim

    Chief Executive Officer at AT-31 BIO Inc.

    Daegu, South Korea